Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Open House Drug Discount Agreements Botulinum Toxin Type A, Finished Drug Name: Xeomin(R), Atc M03ax21

Drug Discount Contracts According to § 130A Paragraph 8 Sgb V in the Context of Open House Procedures

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Contracts for Multiple Active Ingredients/Active Ingredient Combinations

Open House Original Discount Contracts 2023-01 - Dolutegravir

Open House Original Rebate Agreements 2023-02 - Lamivudine/Abacavir/Dolutegravir (Drug Combination)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Biologics Rebate Contracts 2022-24 - Natalizumab (Dosage Form for Subcutaneous Injection)

Open House Biologics Rebate Agreements 2022-23 - Natalizumab (Dosage Form for Intravenous Use)

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Mepolizumab (Atc Code: R03dx09).